Evaluation of Anticancer Activity of Ethanolic and Ethylacetoacetate Extracts of Sweet Cherry Against Human Breast Cancer Cell Line MCF-7

Abstract

MCF-7 is a breast cancer cell line isolated in 1970 from a 69-year-old Caucasian woman. MCF-7 is the acronym of Michigan Cancer Foundation-7, referring to the institute in Detroit where the cell line was established in 1973 by Herbert Soule and co-workers. The MCF7 line retains several characteristics of differentiated mammary epithelium including ability to process estradiol via cytoplasmic estrogen receptors and the capability of forming domes. The cells express the WNT7B oncogene. Growth of MCF7 cells is inhibited by tumor necrosis factor alpha (TNF alpha). Secretion of IGFBP's can be modulated by treatment with anti-estrogens. PIK3CA helical mutations were identified in MCF-7, but with low AKT activation. The main objective of the present research work is to isolate the bioactive molecules and evaluate the in vitro anticancer activity of ethanolic and ethyl acetoacetate extracts of sweet cherry (EEC and EAAEC) of Prunus avium. The in vitro anticancer activity was carried out against human breast cancer cell line MCF-7 by MTT assay. The results obtained from the in-vitro studies performed by MTT assay by using human breast cancer cell line MCF-7 displayed that the various extracts of sweet cherry (EEC and EAAEC) possessed a very good anticancer activity. From the present studied it had been concluded that EEC and EAAEC, all were exhibiting the potential capability to inhibit the cancer cell when compared with standard drug doxorubicin and the cell growth inhibition of EEC and EAAEC was found to be the highest 92.90% growth inhibition at 10 μg (IC50 = 2.4 μg/ml) and EAAEC with the 92.49% growth inhibition at 10 μg (IC50 = 2.9 μg/ml).